Actively building life science companies

5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors.

Scroll to experience 5AM Ventures

Supporting companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science.

Read Me

Nouscom Announces Promotion of Richard Davis to Chief Operating Officer
Read Me

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting
Read Me

Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
Read Me

scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX® New Drug Application
Read Me

Nouscom Announces Janssen Receives U.S. FDA IND Clearance for VAC85135, an “Off-The-Shelf” Cancer Immunotherapy Developed Using Nouscom’s Proprietary Viral Vector Platform

Pushing the healthcare industry forward

$ 0 B

UNDER MANAGEMENT

We’re a life science venture capital firm founded in 2002 and currently investing $450M from 5AM Ventures VII and $300M from 5AM Opportunities II.
0

PORTFOLIO COMPANIES

Our focus is biopharmaceuticals, drug delivery technologies and life science instruments.
0

ONGOING CLINICAL TRIALS

Historically our portfolio companies have had over 80,000 patients enrolled across 8,000 test sites in clinical trials.

San Francisco, CA

Boston, MA

© 2022 5AM Venture Management LLC